Systemic antibiotics: A review and their use in chronic wounds

Dermatologic Therapy

Volumn 9, Issue , 1999, Pages 44-62

  Hernandez Jr , Robert ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; AMIKACIN; AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZTREONAM; BACAMPICILLIN; BEEPEN; BENZATHINE PENICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBENICILLIN; CARINDACILLIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAMANDOLE; CEFAMANDOLE NAFATE; CEFAPIRIN; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFMETAZOLE; CEFONICID; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFTAZIDIME; CEFTIBUTEN; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOXACILLIN; DICLOXACILLIN; DIRITHROMYCIN; ENOXACIN; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; LORACARBEF; MACROLIDE; MEROPENEM; METICILLIN; MEZLOCILLIN; NAFCILLIN; NALIDIXIC ACID; NEOMYCIN; NETILMICIN; NORFLOXACIN; OFLOXACIN; ORPENEED; OXACILLIN; PENICILLIN G; PENICILLIN G POTASSIUM; PENICILLIN G SODIUM; PENICILLIN V; PENICILLIN V POTASSIUM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SPECTINOMYCIN; STREPTOMYCIN; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TOBRAMYCIN SULFATE; TROVAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; AGING; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTHROPATHY; DIARRHEA; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG STRUCTURE; DRUG USE; HEART ARREST; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; REVIEW; TOPICAL DRUG ADMINISTRATION; VOMITING; WOUND CARE; WOUND HEALING; WOUND INFECTION;

EID: 0032993091     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Sandea MA, Mandell GL. Antimicrobial agents: general considerations. In: Gilman, Goodman, Rall, Murad, ed. Chemotherapy of microbial disease. The pharmacological basis of therapeutics. 7th edn. New York: Macmillan, 1985.
2. Lyons AS, Petrocelli RJ. Medicine: an illustrated history. New York: Harry N. Abrams, 1987.
3. Bush LM, Calmon J, Johnson CC. Newer penicillins and beta-lactamase inhibitors. Infect Dis Clin North Am 1995: 9: 653-679.
4. Donowitz GR, Mandell GL. Beta-lactam antibiotics. Part I. N Engl J Med 1988: 318: 419-426.
5. Nathwani D, Wood MJ. Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 1993: 45: 866-894.
6. Mosby's GenRx, p. 1689.
7. Atkinson BA, Lorian V. Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. J Clin Microbiol 1984: 20: 791.
8. Maranan MC, Moreira B, Boyle-Vavra S et al. Antimicrobial resistance in staphylococci. Infect Dis Clin North Am 1997: 11: 813-837.
9. Nathwani D, Wood MJ. Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 1993: 45: 866-894.
10. Donowitz GR, Mandell GL. Beta-lactam antibiotics. Part I. N Engl J Med 1988: 318: 419-426.
11. Mandell GL, Douglas RG, Bennett JE, ed. Principles and practice of infectious diseases. 3rd edn. New York: Churchill Livingstone, 1990.
12. Archer GL, Polk RE. Treatment and prophylaxis of bacterial infections. In: Braunwald E, Fauci AS, Isselbacher KJ, Kaspar DL, Martin JB, Wilson JD, ed. Harrison's principles of internal medicine. 13th edn. New York: McGraw-Hill, 1994: 593-607.
13. Goodman LS, Limbird LE, ed. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996.
14. Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993: 31(suppl A): 9-21.
15. Labia R, Bathelemy M, Peduzzi J. Molecular aspects of beta-lactamas inhibition and inactivation by clavulanic acid: a review. Drugs Exp Clin Res 1985: ii: 765-770.
16. Fairley CK, Boyd I, Purcell P, McNeil J. Flucloxacillin jaundice. Lancet 1992: 339: 679.
17. Fairley CK, McNeil JJ, Desmond P et al. Risk factors for development of flucloxacillin associated jaundice. Br Med J 1993: 306: 233-235.
18. Saliba B. Oxacillin hepatotoxicity in HIV-infected patients. Ann Intern Med 1994: 120: 1048.
19. Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. I. β-lactam antibiotics and related compounds. J Am Acad Dermatol 1997: 37: 149-165.
20. Ennis DM, Cobbs CG. The newer cephalosporins: aztreonam and imipenem. Infect Dis Clin North Am 1995: 9: 687-712.
21. AMA. Drug evaluations. 6th edn. Chicago: American Medical Association, September 1986: 1337-1394.
22. Sanford JP, Gilbert DN, Moellering RC, Sande MA. Guide to antimicrobial therapy. 28th edn.
23. Levine BB. Antigenicity and cross reactivity of penicillins and cephalosporins. J Infect Dis 1973: 128: 364-366.
24. Smith GH. Oral cephalosporins in perspective. Ann Pharmacother 1990: 24: 45-51.
25. Parish LC, Cochetto DM, Werner K et al. Cephalosporin therapy in dermatologic practice. Clin Dermatol 1992: 9: 459-469.
26. Nadelman RB, Luger SW, Frank E et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992: 117: 273-280.
27. Drusano GL, Hutchinson M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995: 96: 11-16.
28. Calandra GB, Raupp W, Brown KR. Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetes. Scand J Infect Dis 1987: 52(suppl 1): 15-19.
29. Eng RHK, Munsif AN, Yangco BG et al. Seizure propensity with imipenem. Arch Intern Med 1989: 149: 1881-1883.
30. Calandia GB, Lyndick E, Carrigan J et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988: 84: 911-918.
31. Norrby SR. Carbepenems. Med Clin North Am 1995: 79: 745-759.
32. Neu HC. Aztreonam: the first monobactam. Med Clin North Am 1988: 72: 555-566.
33. Lundstrum TS, Sobel JD. Vancomycin, trimethoprimsulfamethoxazole and rifampin. Infect Dis Clin North Am 1995: 9: 747-767.
34. Zuckerman JM, Kaye KM. The newer macrolides. Infect Dis Clin North Am 1995: 9: 731-747.
35. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin and roxithromycin. Ann Pharmacother 1992: 26: 45-55.
36. Hardy DJ, Swanson RN, Rode RA et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990: 34: 1407-1413.
37. Stein GE, Havlichek DH. The new macrolide antibiotics: azithromycin and clarithromycin. Postgrad Med 1992: 92: 269-280.
38. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992: 11: 137-152.
39. Franck N, Cabie A, Villete B et al. Treatment of Mycobacterium chelonae-induced skin infection with clarithromycin. J Am Acad Dermatol 1993: 28: 1019-1021.
40. Lassus A. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990: 25(suppl A): 115-121.
41. Parish LC and the Clarithromycin Study Group. Clarithromycin in the treatment of skin and akin structure infections: two multicenter clinical studies. Int J Dermatol 1993: 32: 528-532.
42. Lester GY, Froelich EJ, Gruett MD et al. 1-8-Naphthyridine derivatives: a new class of chemotherapeutic agents. J Med Pharm Chem 1962: 5: 1063.
43. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am 1995: 9: 715-733.
44. Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc 1991: 66: 1249-1259.
45. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991: 324: 384-394.
46. Legan E. The new-generation quinolones: steady progress. Adv Ther 1992: 9: 215-221.
47. Guay DRP. The role of the fluoroquinolones. Pharmacotherapy 1992: 12(6 Pt 2): 71S-85S.
48. Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991: 114: 424-426.
49. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987: 33: 346-391.
50. Peterson LR, Lissack LM, Canter K et al. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 1989: 86: 801-808.
51. Neuman M. Clinical pharmacokinetics of the newer antimicrobial 4-quinolones. Clin Pharmacokinet 1988: 14: 96-121.
52. Adhami S, Wise R, Wiston D et al. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother 1984: 13: 96-121.
53. Fillastre JP, Leroy A, Moulin B et al. Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother 1990: 26(suppl B): 51-60.
54. Nix DE, DeVito JM. Ciprofloxacin and norfloxacin, two flouroquinolone antimicrobials. Clin Pharm 1987: 6: 105-117.
55. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985: 28: 716-721.
56. Gentry LO, Ramires-Rhonda CH, Rodriguez-Noriega et al. Oral ciprofloxacin versus parenteral cefotaxime in the treatment of difficult skin and skin structure infections. Arch Intern Med 1989: 149: 2579-2588.
57. Gentry LO, Rodriguez-Gomez G, Zeluff BJ et al. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med 1989: 87(suppl 6C): 57S-60S.
58. Robson MC. Wound infection. A failure of wound healing caused by an imbalance of bacteria. Wound healing. Surg Clin North Am 1997: 77: 637-650.
59. Mertz PM, Ovington LG. Wound healing microbiology. Wound healing. Dermatol Clin 1993: 11: 739-747.
60. Neidner R, Schöpf E. Wound infections and antibacterial therapy. In: Westerhof W, ed. Leg ulcers: diagnosis and treatment. New York: Elsevier Science Publishers, 1993: 293-303.
61. Schraibmann IG. The significance of β-hemolytic streptococci in chronic leg ulcers. Ann R Coll Surg 1990: 72: 123-124.
62. US Agency for Health Care Policy and Research (personal communication).
63. Craig WA, Andes DR. Parenteral versus oral antibiotic therapy. Antimicrobial therapy I. Med Clin N Am 1995: 79: 497-509.
64. Craig WA. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur J Clin Microbiol Infect Dis 1993: 12(suppl 1): S6.
65. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991: 74(suppl 5A): 142S.
66. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993: 37: 10073.
67. Lettieri JL, Rogge MC, Kaiser L et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992: 36: 993.
68. Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994: 33: 169.
69. Gentry LO, Ramirez-Rhonda CH, Rodriguez-Noriega E et al. Oral ciprofloxacin vs. parenteral cefotaxime in the treatment of difficult skin and skin structure infections. Arch Intern Med 1989: 149: 2579.
70. Gentry LO, Rodriguez-Gomez G, Zeuff BJ et al. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skins and skin structure infections. Am J Med 1989: 87(suppl 6C): 57S.
71. Gentry LO, Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med 1989: 87(suppl 5A): 169S.
72. Del Rosal PL, Del Rosal LL, Riosvelasco CA et al. Brief report: prospective, controlled, randomized, non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of severe surgical infections. Am J Med 1989: (suppl 5A): 183S.